RxDoctor Payments Data

Sallie Dalton, APRN

Psychiatric/Mental Health · Philadelphia, MSNPI 1104472653

Payments from drug & device makers

$3,198in general payments, 2019–2025

Across 188 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$749
  • AbbVie$543
  • Teva Pharmaceuticals USA, Inc.$526
  • Vanda Pharmaceuticals Inc.$197
  • Takeda Pharmaceuticals U.S.A., Inc.$152
  • H2-pharma, LLC$150
  • plus $881 from 13 others

What the payments were for

  • Speaking & faculty fees$1505%
  • Food & beverage$2,83189%
  • Education$2177%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,198 in reported general payments places this provider in the 80th percentile of 486 psychiatric/mental health providers in Mississippi.

See all psychiatric/mental health providers in Mississippi

Medicare billing

Part B allowed, 2024
$11,020
Medicare patients
26
Services billed
126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole17$36,739
Abilify MaintenaAripiprazole11$29,686
Effexor XrVenlafaxine Hcl13$22,463
VraylarCariprazine Hcl13$18,667
TrintellixVortioxetine Hydrobromide12$5,593
Vilazodone Hcl20$2,867
Lisdexamfetamine Dimesylate11$2,049
Oxcarbazepine56$1,991
Zolpidem Tartrate ErZolpidem Tartrate11$1,469
Haloperidol Decanoate12$1,319
Buspirone Hcl33$1,222
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine21$941
Desvenlafaxine Succinate ErDesvenlafaxine Succinate23$587
Quetiapine Fumarate23$572
Methylphenidate ErMethylphenidate Hcl12$393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$111$66,42628 claims
AbbVieVraylar$543$18,66713 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$152$5,59312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 486 psychiatric/mental health providers in Mississippi.

Other psychiatric/mental health in Philadelphia

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →